Radius Health Inc logo

RDUS - Radius Health Inc Share Price

$12.02 0.0  0.0%

Last Trade - 05/08/20

Mid Cap
Market Cap £425.3m
Enterprise Value £480.0m
Revenue £146.0m
Position in Universe 2847th / 6368
Unlock RDUS Revenue
Relative Strength (%)
1m -19.3%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -59.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 22.1 99.2 173.3 217.9 265.3
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Radius Health Inc revenues increased 61% to $47.9M. Net loss decreased 12% to $37.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General and administrative decrease of 12% to $36.4M (expense), Other income (expense) increase from $4K to $11K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


RDUS Revenue Unlock RDUS Revenue

Net Income

RDUS Net Income Unlock RDUS Revenue

Normalised EPS

RDUS Normalised EPS Unlock RDUS Revenue

PE Ratio Range

RDUS PE Ratio Range Unlock RDUS Revenue

Dividend Yield Range

RDUS Dividend Yield Range Unlock RDUS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RDUS EPS Forecasts Unlock RDUS Revenue
Profile Summary

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated February 4, 2008
Public Since June 6, 2014
No. of Shareholders: n/a
No. of Employees: 383
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 46,388,624
Free Float (0.0%)
Eligible for
RDUS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for RDUS
Upcoming Events for RDUS
Monday 10th August, 2020
Q2 2020 Radius Health Inc Earnings Call
Tuesday 3rd November, 2020 Estimate
Q3 2020 Radius Health Inc Earnings Release
Frequently Asked Questions for Radius Health Inc
What is the Radius Health Inc share price?

As of 05/08/20, shares in Radius Health Inc are trading at $12.02, giving the company a market capitalisation of £425.3m. This share price information is delayed by 15 minutes.

How has the Radius Health Inc share price performed this year?

Shares in Radius Health Inc are currently trading at $12.02 and the price has moved by -44.2% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Radius Health Inc price has moved by -51.33% over the past year.

What are the analyst and broker recommendations for Radius Health Inc?

Of the analysts with advisory recommendations for Radius Health Inc, there are there are currently 1 "buy" , 6 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Radius Health Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Radius Health Inc next release its financial results?

Radius Health Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Radius Health Inc dividend yield?

Radius Health Inc does not currently pay a dividend.

Does Radius Health Inc pay a dividend?

Radius Health Inc does not currently pay a dividend.

When does Radius Health Inc next pay dividends?

Radius Health Inc does not currently pay a dividend.

How do I buy Radius Health Inc shares?

To buy shares in Radius Health Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Radius Health Inc?

Shares in Radius Health Inc are currently trading at $12.02, giving the company a market capitalisation of £425.3m.

Where are Radius Health Inc shares listed? Where are Radius Health Inc shares listed?

Here are the trading details for Radius Health Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: RDUS
What kind of share is Radius Health Inc?

Based on an overall assessment of its quality, value and momentum, Radius Health Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Radius Health Inc share price forecast 2020?

Shares in Radius Health Inc are currently priced at $12.02. At that level they are trading at 97.25% discount to the analyst consensus target price of 0.00.

Analysts covering Radius Health Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.424 for the next financial year.

How can I tell whether the Radius Health Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Radius Health Inc. Over the past six months, the relative strength of its shares against the market has been -36.17%. At the current price of $12.02, shares in Radius Health Inc are trading at -31.32% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Radius Health Inc PE Ratio?

We were not able to find PE ratio data for Radius Health Inc.

Who are the key directors of Radius Health Inc?

Radius Health Inc's management team is headed by:

Kurt Graves - CHM
Owen Hughes - CHM
Willard Dere - IND
Anthony Rosenberg - IND
Catherine Friedman - IND
Jean-Pierre Garnier - IND
Jose Carmona - CFO
Jesper Hoiland - PRE
Joseph Kelly - SVP
Chhaya Shah - SVP
Charles Morris - OTH
Jessica Hopfield - IND
G. Kelly Martin - PRE
Who are the major shareholders of Radius Health Inc?

Here are the top five shareholders of Radius Health Inc based on the size of their shareholding:

Bellevue Asset Management AG Investment Advisor
Percentage owned: 14.94% (6.93m shares)
BB Biotech Fd Mutual Fund
Percentage owned: 14.94% (6.93m shares)
T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 11.87% (5.51m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 10.37% (4.81m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.3% (4.32m shares)
Similar to RDUS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.